Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Filgotinib in active noninfectious uveitis
NCT03207815Phase 2Terminated
- Sponsor
- Gilead Sciences
- Start
- Jul 2017
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 2, randomised, double-blind trial of filgotinib in noninfectious uveitis, sponsored by Gilead Sciences. Primary endpoint: Percentage of Participants Failing Treatment for Active NonInfectious Uveitis at 24 weeks. Started Jul 2017; status: terminated.
02
Drugs
filgotinib
03
Conditions
noninfectious uveitis
Beyond the preview
Go deeper on NCT03207815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03207815.